58 completed, 17 active not recruiting, 16 recruiting, 14 terminated. 126 Phase 2, 27 Phase 1, 3 Phase 3.
Follow Brentuximab Vedotin: new trials by email Literature Review of Brentuximab Vedotin trials Research Report on Brentuximab Vedotin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment Biospecimen Collection, Brentuximab Vedotin, Computed Tomography - Classic Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 23 | 2026-10-01 | 2026-08-20 |
| Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL) Brentuximab Vedotin (Bv), Lisaftoclax (APG-2575) - Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Not yet recruiting | Peking University First Hospital | 46 | 2026-07-31 | 2026-07-23 |
| Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL Vinblastine (Velban), Brentuximab vedotin (Adcetris), Nivolumab (Opdivo) - Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Recruiting | New York Medical College | 20 | 2025-08-07 | 2026-05-20 |
| BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma Brentuximab Vedotin, Etoposide, Cyclophosphamide - Hodgkin Lymphoma, Advanced Hodgkin Lymphoma | Phase 2 | Recruiting | University of Miami | 48 | 2025-07-15 | 2025-11-03 |
| Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment Brentuximab Vedotin for Injection, response-adapted radiation, Doxorubicin - Classical Hodgkin Lymphoma, Child | Phase 2 / Phase 3 | Recruiting | Children's Cancer Group, China | 96 | 2024-09-25 | 2026-03-19 |
| Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. Chidamide; Decitabine; Anti-PD-1 Antibody, Brentuximab Vedotin, anti-PD-1 antibody. - Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma | Phase 2 | Recruiting | Chinese PLA General Hospital | 100 | 2024-06-01 | 2026-01-02 |
| A Study of BV-AVD in People With Bulky Hodgkin Lymphoma Brentuximab vedotin, Doxorubicin, Vinblastine - Hodgkin Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2024-04-17 | 2026-04-23 |
| Open Label Extension Study of Brentuximab Vedotin in Early dcSSc Brentuximab vedotin - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 3 | 2024-02-14 | 2026-09-30 |
| PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab - Hodgkin Lymphoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2023-12-14 | 2026-10-06 |
| Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma Brentuximab vedotin, Pembrolizumab - T-Cell Lymphoma | Phase 2 | Recruiting | Yale University | 32 | 2023-07-10 | 2026-06-11 |
| A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) Brentuximab Vedotin, Cyclophosphamide, Doxorubicin - Lymphoma | Phase 2 | Active not recruiting | Takeda | 52 | 2023-02-10 | 2026-06-12 |
| Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma Gemcitabine, Dexamethasone, Cisplatin - Hodgkin Lymphoma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 84 | 2022-11-01 | 2026-02-02 |
| Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma Brentuximab Vedotin 50 MG [Adcetris] - Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | Hospital Regional de Alta Especialidad del Bajio | 20 | 2022-10-18 | 2025-03-12 |
| Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides Brentuximab vedotin - Mycosis Fungoides | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2022-10-13 | 2026-07-29 |
| BV-AVD-R Treatment Children Hodgkin's Lymphoma Brentuximab vedotin, Rituximab, Doxorubicin - Hodgkin Lymphoma | Phase 2 | Unknown | Beijing Children's Hospital | 44 | 2022-10-01 | 2024-01-12 |
| Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above Pembrolizumab, Doxorubicin, Vinblastine - Classical Hodgkin Lymphoma | Phase 2 | Active not recruiting | University of Virginia | 24 | 2022-07-26 | 2026-05-14 |
| Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma Brentuximab Vedotin in Combination with Tislelizumab - NK/T Cell Lymphoma Nos | Phase 2 | Unknown | Shanghai Zhongshan Hospital | 40 | 2022-06-01 | 2022-04-07 |
| Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors Brentuximab Vedotin, Hematopoietic Cell Transplantation, Nivolumab - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 | Recruiting | Emory University | 46 | 2022-05-02 | 2026-09-08 |
| Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma Brentuximab vedotin - Relapsed/Refractory Classical Hodgkin Lymphoma | Phase 2 | Unknown | National Cancer Center, Korea | 30 | 2022-03-01 | 2022-02-17 |
Showing 20 of 126. Sign in to see all of them.
Hodgkin Disease (53) · Lymphoma (19) · Lymphoma, Large-Cell, Anaplastic (15) · Hematologic Diseases (9) · Lymphoma, Non-Hodgkin (9) · Lymphoma, T-Cell (9) · Recurrence (9) · Lymphoma, T-Cell, Peripheral (7) · Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, T-Cell, Cutaneous (6) · Mycosis Fungoides (6) · Enteropathy-Associated T-Cell Lymphoma (4) · Immunoblastic Lymphadenopathy (4) · Lymphatic Diseases (4) · Lymphoma, B-Cell (4)
Seagen Inc. (16) · National Cancer Institute (NCI) (8) · City of Hope Medical Center (7) · M.D. Anderson Cancer Center (7) · Fondazione Italiana Linfomi - ETS (5) · Memorial Sloan Kettering Cancer Center (4) · The Lymphoma Academic Research Organisation (4) · Northwestern University (3) · Takeda (3) · University of Cologne (3) · University of Washington (3) · Academic and Community Cancer Research United (2) · Bristol-Myers Squibb (2) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (2) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2)
United States (84) · France (16) · Italy (16) · Canada (12) · Spain (10) · United Kingdom (7) · Belgium (6) · China (6) · Czechia (5) · Germany (5) · Netherlands (5) · Poland (5) · South Korea (3) · Australia (2) · Denmark (2)
Alex F Herrera (3) · Alex Herrera (2) · Alison Moskowitz, MD (2) · Neil Josephson, MD (2) · Peter Borchmann, Prof. (2) · Vittorio Stefoni, MD (2) · Abraham Fong, MD, PhD (1) · Adam Petrich, MD (1) · Ajay Gopal (1) · Ajay K. Gopal (1) · Alessandro M Gianni, MD (1) · Allison Moskowitz, MD (1)
PMID 40135712, PMID 17242396, PMID 24652992, PMID 28188133, PMID 28974506, PMID 32596842, PMID 33827139, PMID 37505794, PMID 12097283, PMID 1244564, PMID 18079362, PMID 19466965, PMID 19597183, PMID 19789316, PMID 21270441, PMID 21576639, PMID 22454421, PMID 22510871, PMID 22614995, PMID 22919026, PMID 23624209, PMID 23674495, PMID 23716537, PMID 23818604, PMID 24359243, PMID 24642247, PMID 25113753, PMID 25533035, PMID 25573987, PMID 25683846, PMID 26195720, PMID 26211987, PMID 26377597, PMID 26542718, PMID 26770954, PMID 26994848, PMID 27432875, PMID 27574190, PMID 27868471, PMID 28034070, PMID 28486951, PMID 28570279, PMID 28600132, PMID 28879531, PMID 28911074, PMID 28980004, PMID 29038340, PMID 29143824, PMID 29222199, PMID 29229594
P30CA033572 (4), P30CA015704 (3), 2008 (2), 2014 (2), 2015 (2), 2016 (2), P30CA015083 (2), U10CA098543 (2), U10CA180820 (2), U10CA180886 (2), 2018 (1), 2023 (1), N01CM17003 (1), N01CM62202 (1), P01CA018029 (1)